Academic Half-Day The Chemical Basis for Neuronal Communication

1. Academic Half-DayThe Chemical Basis for Neuronal Communication Marie-Pierre Thibeault-Eybalin, R4 November 5th, 2008

2. Introduction • 100 billion (1011) neurons in the brain • Up to 100,000 terminal contacts / neuron • 1016 connections between neurons / brain • Connections = Synapses • Chemical messenger is released at pre-synaptic membrane of axon or dendrite terminal • It travels across synaptic cleft • It binds onto its receptor on post-synaptic membrane of other neuron • It activates effector system • Chemical messenger may be released at non-synaptic locations to influence distant neurons

3. Criteria to define chemical messenger as neurotransmitter • Localization: A putative neurotransmitter must be localized to the presynaptic elements of an identified synapse and must be present also within the neuron from which the presynaptic terminal arises. • Release: The substance must be shown to be released from the presynaptic element upon activation of that terminal and simultaneously with depolarization of the parent neuron. • Identity: Application of the putative neurotransmitter to the target cells must be shown to produce the same effects as those produced by stimulation of the neurons in question.

4. Examples of neurotransmitters

5. Synaptic transmission • Variable synaptic delay from pre-synaptic neurotransmitter release to excitation or inhibition of post-synaptic neuron • Synaptic delay depends on complexity of transduction mechanisms at post-synaptic membrane

6. Sequence of events

7. Regulatory mechanisms • To regulate amount of neurotransmitter release • Pre-synaptic receptor-mediated autoregulation • Neurotransmitter in synaptic cleft binds to pre-synaptic receptor • Inhibitory feedback mechanism • Retrograde transmission • 2nd chemical messenger diffuses from post-synaptic to pre-synaptic membranes, e.g. NO

8. Secretory vesicles • Small = Synaptic vesicles • For small molecules • Synthesized within vesicles, e.g. NE or uploaded by high-affinity ATP-proton-coupled transporters in terminals, e.g. ACh • Recycled • 50 nm diameter • Cluster in active zones • Large dense-cored vesicles • For neuropeptides, "built-in" in neuronal soma ± co-stored small molecule • Not-recycled • 75-150 nm diameter • Found in intraneuronal locations + terminals, less numerous • Neurosecretory vesicles • Hypothalamic neuron terminals in neurohypophysis • For neurohormones • 150-200 nm diameter

9. Secretory vesicles

10. Exocytic release Fusion pore Docking complex

11. Signal transduction • Most receptors are transmembrane glycoproteins • Binding of neurotransmitter to receptor induces conformational change • 4 transduction mechanisms • Ligand-gated ion channels • G-protein-coupled receptors • Enzymes e.g. tyrosine kinase • Ligand-dependent regulators of nuclear transcription e.g. testosterone • Receptors often named after family of neurotransmitters they bind e.g. cholinergic and adrenergic receptors • Multiple subtypes based on response • Nicotinic ACh receptors usually excitatory • Muscarinic ACh receptors usually inhibitory • Individual neurotransmitter family members of have different potency • Rank order of potency according to EC50% • Concentration of individual neurotransmitter required to reach 50% of maximal response expected • The same neurotransmitter may have excitatory or inhibitory responses depending on receptor type

12. Structure of neurotransmitter receptors Ligand-gated ion channels • Multiple subunits = transmembrane glycoproteins connected via intra-and extra-cellular loops • Cylindrical • Binding site in transmembrane portion • Conformation changes opens gate inside channel • Selectively pass small ions • 2 genetic families based on AA sequence homology • Nicotinic ACh, serotonin, GABA, glycine • Glutamate

13. G-protein-coupled receptors • Glycoprotein chains with multiple transmembrane loops • -helices • β-pleated sheets • Binding site in transmembrane or extra-cellular portion • 3 components • Receptor • GTP-binding heterotrimer • Effector protein (enzyme or ion channel) • Examples • Rhodopsin • Odorants • Biogenic amines • Bioactive peptides • β2-adrenergic receptor

14. G-protein action

15. Examples of effector proteins

16. Receptor regulation • Desensitization • Reduction in receptor agonist-induced response after seconds to minutes of stimulation mediated by conformational changes • Homologous • Heterologous • Phosphorylation of intracellular portion of receptor altering its binding affinity • Downregulation of receptor number at post-synaptic membrane • Internalization of receptor by invagination of post-synaptic membrane

17. Maintenance of synaptic environment • To reduce or eliminate neurotransmitters in synaptic cleft • Enzymatic degradation • ACh cleaved by acetylcholinesterase • Neuropeptides degraded by peptidases • Transporter-mediated reuptake of small molecules (not neuropeptides) by pre-and post-synaptic neuron or glia (extraneuronal monoamine transport; EMT) • NET for norepinephrine • DAT for dopamine • SERT for serotonin • After reuptake, neurotrasmitter either recycled or degraded by mitochondria (MAO) • COMT for norepinephrine

18. Pharmacologic modification of synaptic transmission Drugs may affect: • Neurotransmitter synthesis • Vesicular uptake and storage • Depolarization-induced exocytosis • Neurotransmitter receptor binding • Termination of neurotransmitter action • Post-synaptic effector system

19. Metyrosine for pheochromocytoma -Methyldopa VAMT Reserpine MAO inhibitors Guanethidine Yohimbine Cocaine Propranolol

20. Synopsis of clinical points • Many drugs function by altering chemical transmission at the synaptic cleft. • Neuropeptides play a role in the body's response to stress. • Some drugs must traverse the plasma membrane to access receptors. • Epinephrine is used in cardiopulmonary resuscitation and to treat anaphylactic reactions. • The excess production of catecholamines, seen in tumors such as pheochromocytoma, can be treated by the drug metyrosine. • Reserpine is sometimes used to treat hypertension. • Reserpine may precipitate Parkinson-like symptoms or galactorrhea, or worsen clinical depression. • α-Methyldopa is effective for managing hypertension during pregnancy. • The side effects of guanethidine include reduced heart rate, nasal congestion, and orthostatic hypotension. • Propranolol is used in the management of angina pectoris, hypertension, and congestive heart failure. • Yohimbine may be effective in treating male impotence of vascular or psychogenic origin. • Amphetamines enhance motor performance and relieve fatigue; these are habit-forming if used inappropriately.